Key words: Rituximab
; Lymphoma, non-Hodgkin--therapy; Lymphoma, follicular; Maintenance chemotherapy; Treatment outcome
iBio (IBIO) announced that it has expanded the scope of its business venture with CC-Pharming by granting it an exclusive, royalty-bearing commercial license to iBio's bio-better rituximab
product candidates for the territory of China.
Shanafelt, M.D., from Stanford University in California, and colleagues randomly assigned 529 patients (aged ≤70 years) with previously untreated CLL in a 2:1 ratio to receive either ibrutinib and rituximab
for six cycles (after a single cycle of ibrutinib alone) followed by ibrutinib until disease progression (354 patients) or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab
for six cycles (175 patients).
- The United States Food and Drug Administration has approved Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab
), for the treatment of adult patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis, US-based pharmaceutical company Pfizer Inc.
IBI301, a co-developed biosimilar product candidate of rituximab
(MabThera/Rituxan), is expected to offer a high-quality and affordable alternative to patients in China.
The pivotal study, PIX301 was an open-label, randomised, Phase III study comparing Pixuvri monotherapy with physician's choice of treatment in 140 patients with relapsed or refractory aggressive non-Hodgkin lymphoma, 50% of whom had been previously treated with rituximab
Approval based on Phase 3 AUGMENT study, which showed the combination significantly improved median progression-free survival versus rituximab
B cell cross match may remain positive post desensitization due to the effects of Rituximab
which itself, is a monoclonal antibody.
Through the decades, rituximab
, cyclophosphamide, doxorubicin, prednisone, and vincristine (R-CHOP) therapy has dramatically improved the clinical outcome due to the introduction of rituximab
ORLANDO -- Rituximab
is "quickly emerging" as frontline therapy for pemphigus, Carolyn Kushner said at the International Investigative Dermatology meeting.